WALID mohamed Madkor

Strong track record on both the local and international level 1. In 2014, the outsourcing products achieve 55 MLE with 11% growth ( Feldene amp. achieve 14 MLE with 9% while Feldene oral achieve 15 MLE with 7% growth) and we were able to switch Multi pharm outsourced products to UCP without compromising the sales revenue. 2. In 2015 ,I work closely with Pfizer and UCP management to deliver the challenging financial outcomes that are needed to achieve Pfizer and UCP sales Objectives and to achieve 60 MLE (YTD P10,2015 sales 46.5 MLE that 99% Vs target with 9% growth) 3. In 2017 , I get new responsibility as marketing manager to lead Pfizer Anti –infective that represent 758 MLE sales revenue with 58% share and my team composed of three Product Manager responsible for Pfizer Anti-bacterial and Anti-Fungal portfolio 4. In 2017, I shared in the Portfolio optimization project that has the responsibility to assign the new team structure (Hospital and Private ) and the portfolio.